Note: This therapeutic review was conducted in 2014 and there is now an update in progress. Refer to the current therapeutic review, as well as a large number of other reports, bundled together in our...
The Canadian Agency for Drugs and Technologies in Health (CADTH) examined the clinical and economic impact of new and existing drugs to treat pulmonary arterial hypertension (PAH). The review included...
The Canadian Agency for Drugs and Technologies in Health (CADTH) has examined the comparative efficacy and safety of drug therapies for relapsing-remitting multiple sclerosis (RRMS). The review...
Warfarin has been the mainstay of oral anticoagulant therapy for many years. Now, new oral anticoagulants are being used to prevent stroke and other thromboembolic events in patients with atrial...
CADTH undertook a project on genetic testing for factor V Leiden and prothrombin gene mutations — both of which can lead to an increased risk of developing blood clots (thrombophilia). The project...
CADTH has undertaken an optimal use project to assess the clinical and economic impact of point-of-care (POC) testing of the international normalized ratio (INR) for patients taking warfarin or other...
When patients present to the emergency department with chest pain, investigations are needed to rule out acute coronary syndrome and acute myocardial infarction. One of the investigations used is...
Warfarin has been the mainstay of oral anticoagulant therapy for more than 60 years. The effectiveness of warfarin for the prevention of stroke in patients with atrial fibrillation is well established...
The Canadian Agency for Drugs and Technologies in Health (CADTH) has undertaken an optimal use project to assess the clinical and economic impact of using atypical antipsychotic combination therapy...